Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 1/20 | 0.50 |
| ▸ | TYRO3 | Q06418 | 17/20 | 0.49 |
| ▸ | MERTK | Q12866 | 12/20 | 0.45 |
| ▸ | AXL | P30530 | 11/20 | 0.45 |
| ▸ | BCL6 | P41182 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3494415 | 0.92 | PRKCQ (0.52) | PRKCQTYRO3MERTKAXLCCNT1 | |
| SCHEMBL3496172 | 0.91 | PRKCQ (0.53) | PRKCQTYRO3MERTKAXLCCNT1 | |
| SCHEMBL3496637 | 0.90 | PRKCQ (0.53) | PRKCQTYRO3MERTKAXLCCNT1 | |
| SCHEMBL3494579 | 0.89 | PRKCQ (0.49) | PRKCQTYRO3MERTKAXLCCNE2 | |
| SCHEMBL3496712 | 0.89 | PRKCQ (0.51) | PRKCQTYRO3MERTKAXLBCL6 | |
| SCHEMBL3495453 | 0.89 | PRKCQ (0.53) | PRKCQTYRO3MERTKAXLCCNT1 | |
| SCHEMBL3496359 | 0.87 | PRKCQ (0.51) | PRKCQTYRO3BCL6CCNT1CCNE1 | |
| SCHEMBL3493265 | 0.86 | PRKCQ (0.49) | PRKCQTYRO3MERTKAXLBCL6 | |
| SCHEMBL3495756 | 0.86 | PRKCQ (0.54) | PRKCQTYRO3MERTKAXLBCL6 | |
| SCHEMBL3496411 | 0.86 | PRKCQ (0.53) | PRKCQTYRO3MERTKAXLCCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | claimed |
| US-8993585-B2 | Cyclic amine substituted pyrimidinediamines as PKC inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | PRKCH, PKD2, PRKCQ | PRKCQ 3/4885TYRO3 852/4885MERTK 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.